The success of this financing first shows that the market recognizes and supports Bangyao Bio. With the mission of "leading innovation with gene editing, developing breakthrough therapies, and benefiting all mankind", the business orientation and development direction of Bangyao Bio has been positively responded by the market. Secondly, it also reflects the investment boom of China's biomedical industry. Driven by national policies, the biomedical industry has developed rapidly and attracted a lot of investment. Finally, this financing will also provide more financial support for the future development of Bangyao Bio, help it continue to promote the transformation and landing of cells and genetic drugs, intensify efforts to further accelerate the global R&D layout, help the development of global life sciences, and bring hope to patients with genetic diseases, malignant tumors and autoimmune diseases around the world.
Generally speaking, Bangyao Bio won the 200 million yuan Series B financing led by the Shanghai Free Trade Zone Fund, which is an affirmation of its business development and market prospects, and also indicates that the investment boom in the biomedical industry in China will continue to heat up.